Novavax recently reported the following corporate developments:

Receipt of notification from HHS/BARDA that a potential influenza vaccine development contract is in the "competitive range"; Achievement of positive results from trial of trivalent seasonal influenza vaccine in older adults;Recruitment of new Chief Medical and Chief Scientific Officers and appointment of new Head of Process and Manufacturing Operations and Head of Analytical and Quality Operations;Continued R&D progress in discovery of new targets to broaden vaccine pipeline; Appointment of Dr. James Young, an accomplished and distinguished member of the biotech industry, to the Board of Directors;Completion of construction of vaccine production facility in India by joint-venture company, CPL Biologicals; andReceipt of key technology patent covering production of VLP vaccines from multiple strains of seasonal and pandemic influenza viruses.

SOURCE Novavax, Inc.